Open main menu

Creative Thinking Institute

The AI-native parent company behind Regenemm Healthcare.

Creative Thinking Institute Pty Ltd was founded in October 2019 as a parent innovation company focused on the future of connected healthcare. CTI began with a simple but durable thesis: health technology should connect human performance, physiology, clinical context, and practical care delivery.

CTI's first major product was Regenemm: a mobile digital health application designed to monitor stress, performance, and health outcomes through biometric and psychometric data. From the beginning, Regenemm was built with clinical seriousness through ethics preparation, pilot study design, patient-consent workflows, privacy planning, and machine-learning development.

Today, CTI is the credibility and R&D layer behind Regenemm Healthcare: AI-native clinical infrastructure built to support clinicians, generate safer documentation, produce patient-facing summaries, connect fragmented health data, and operate within a compliance-led framework for secure, auditable, transparent and responsible AI.

Strategic evolution

Regenemm Healthcare is not a 2023 AI land grab. CTI has been building toward AI-enabled healthcare since before generative AI became mainstream: first through stress-performance monitoring, then Australian Government-supported R&D, body movement analysis, wearables and biosensors, then sleep and medical IoT, and now through hub-and-spoke clinical AI infrastructure.

2019-2020

Foundation

CTI was founded in 2019 as the AI-native parent company for clinically grounded digital health, human performance, and biosensor-enabled care.

2020-2021

Regenemm v1

Regenemm began as a React Native mobile application for stress, performance, and preventative health, combining biometric and psychometric data.

2020-2024

Government-supported R&D

CTI received Australian Government R&D support through the Department of Industry, Science and Resources framework for eligible Regenemm research and development activities.

2021-2022

Physiology expansion

The company expanded from stress into physiology: sleep, circadian rhythm, wearable biosensors, soft sensing, movement analysis, rehabilitation monitoring, and medical IoT.

2021-2022

Research discipline

Ethics preparation, pilot planning, grant applications, and partnerships sharpened CTI's evidence base, consent model, and clinical utility.

Late 2022 onward

AI acceleration

Generative AI did not replace CTI's original thesis. It extended existing work in structured health data, biometrics, consent, machine learning, and clinical context.

2023-2026

Regenemm Healthcare

Regenemm Healthcare evolved into AI-native clinical infrastructure for assistants, documentation, patient summaries, interoperability, auditability, and clinician validation.

2026 onward

Hub-and-spoke platform

The platform has matured toward domain-rich clinical spokes connected to a governed hub for persistence, entitlements, distribution, telemetry, and compliance evidence.

The through-line

From human performance to clinical AI infrastructure

The original ambition was not another wellness app. It was an evidence-seeking digital health platform designed to bridge people, practitioners, pharmacists, wearables, and emerging care networks.

Regenemm Healthcare is not designed to overthrow existing clinical systems. It is designed to make them work better: bridging fragmented data, supporting mobile clinicians, enabling offline capture, and creating continuity between patients, practitioners, hospitals, and health infrastructure.

The operating architecture is hub-and-spoke: clinical spokes can own domain intelligence such as documentation, risk assessment, summaries, FHIR construction, and role-specific workflows, while the hub owns persistence, identity, cross-spoke distribution, entitlements, telemetry, and the compliance evidence trail.

Shared transparency is the product: clinicians see what they are entitled to see, patients receive understandable summaries, care teams get legible documentation, and consent, provenance, and audit trails sit underneath every workflow. CTI keeps that philosophy visible at the parent-company level while Regenemm publishes the product-specific trust surfaces for clinical safety, security, privacy and platform review.

Human performance, physiology, clinical context, and practical care delivery belong in one connected healthcare story.
Regenemm began as a human-performance and preventative-health platform, not another wellness app.
The original work connected biometric data, psychometric insight, clinical feedback, practitioner visibility, and patient consent.
Soft sensing and body movement work showed how objective rehabilitation and movement data could support patient-specific recovery plans.
Australian Government-supported R&D helped CTI connect wearables, psychometrics, machine learning, speech processing, LLM summarisation and clinical workflow architecture.
Major grant and research processes gave CTI strategic discipline around evidence, partnerships, regulation, and healthcare value.
CTI has been building toward AI-enabled healthcare since before generative AI became mainstream.
Regenemm Healthcare is designed to make existing clinical systems work better, not overthrow them.
The Hub is the control plane. The spokes are specialist clinical workflows. The patient remains at the centre.
Healthcare AI is only useful if clinicians can trust it, patients can understand it, and organisations can audit it.
AI governance is being built as an operating system: lifecycle controls, impact assessments, provenance, monitoring, executive oversight, and evidence retention.
Human ethics preparation, granular consent, ISO 14971-style risk management and systematic literature review strengthen the clinical validation pathway.
The long-term goal is institutional interoperability; the near-term strategy is practitioner-led adoption and evidence-seeking iteration.
Current product translation

Regenemm drafts. Humans approve.

CTI works with Vanta to support Regenemm Healthcare's formal accreditation and assurance pathway across ISO 27001, ISO 42001, HIPAA, GDPR, and SOC 2 readiness. This reflects the belief that healthcare AI must be secure, auditable, explainable, and accountable from the beginning.

Regenemm's production posture is evidence-gated: identity, access control, audit trail, PHI protection, network exposure, observability, incident response, and change control are treated as operating requirements, not afterthoughts.

The governance model includes executive oversight of AI risk, AI impact assessments, intended-purpose records, system and model cards, data lineage, traceability from requirements to tests and logs, release approvals, monitoring records, and Vanta-linked risk ownership.

Trust is not a marketing claim. It is an engineering requirement.

Regenemm's clinical validation pathway is being developed around participant information and consent materials, investigator documentation, ISO 14971-style risk management, systematic evidence review and human review of AI-generated clinical content.

Visit RegenemmRegenemm Trust CenterClinical safety